years. Table 1 also shows the characteristics of the 203 patients whose clinical histories and images were selected for the study and of the 25 readers who interpreted their data. Table 1. Sample Characteristics As Table 2 shows, interobserver
Search Results
Estanislao Arana, Francisco M. Kovacs, Ana Royuela, Beatriz Asenjo, Fatima Nagib, Sandra Pérez-Aguilera, María Dejoz, Alberto Cabrera-Zubizarreta, Yolanda García-Hidalgo, Ana Estremera, and for the Spanish Back Pain Research Network Task Force for the Improvement of Inter-Disciplinary Management of Spinal Metastasis
Erin E. Hahn, Michael K. Gould, Corrine E. Munoz-Plaza, Janet S. Lee, Carla Parry, and Ernest Shen
adjusted for multiple pairwise comparisons between comorbidity classes by using the Bonferroni correction. Table 1. Patient Characteristics, Cancer Treatment, and Comorbidities Results We identified 7,803 patients with CRC ( Table 1
Christina Signorelli, Claire E. Wakefield, Karen A. Johnston, Joanna E. Fardell, Jordana K McLoone, Mary-Ellen E. Brierley, Maria Schaffer, Elysia Thornton-Benko, Afaf Girgis, W. Hamish Wallace, Richard J. Cohn, and on behalf of the BSU Implementation Group
summarize sample characteristics, analyze feasibility/acceptability, and summarize secondary outcomes. We compared self-efficacy scores preintervention and postintervention using multilevel models (MIXED function). Results Of 36 eligible and contactable
Ishveen Chopra, Malcolm D. Mattes, Patricia Findley, Xi Tan, Nilanjana Dwibedi, and Usha Sambamoorthi
service. Each individual was observed for 48 months ( Figure 1 ). Figure 1. Schematic of the study design. Each individual was observed for 48 months with a 24-month baseline (for identification of CAD and baseline characteristics), 12-month preindex, and
Neil J. Shah, Michael R. Cook, Tianmin Wu, Shaked Lev-Ari, Matthew J. Blackburn, Michael T. Serzan, Adil Alaoui, Jaeil Ahn, and Michael B. Atkins
reported. A Bonferroni-adjusted type I error 2.5% (5%/2) was used for statistical significance. R version 3.4 (R Foundation for Statistical Computing) was used for all statistical analyses. Results Patient Characteristics, irAEs, and Use of SS and
Louisa Liu, Yanghee Woo, Massimo D’Apuzzo, Laleh Melstrom, Mustafa Raoof, Yu Liang, Michelle Afkhami, Stanley R. Hamilton, and Joseph Chao
of expression. After 3 cycles of pembrolizumab, restaging PET/CT demonstrated greater diminishment of the antral tumor and stable intrathoracic nodes. Table 1. Summary of Patient Characteristics, Treatments, and Responses Figure 1
Carrie Zornosa, Jonathan L. Vandergrift, Gregory P. Kalemkerian, David S. Ettinger, Michael S. Rabin, Mary Reid, Gregory A. Otterson, Marianna Koczywas, Thomas A. D'Amico, Joyce C. Niland, Rizvan Mamet, and Katherine M. Pisters
Member Institution. Data collection includes patient, disease, and treatment characteristics that are manually abstracted from medical records by trained data managers at each participating site. Data are abstracted for each patient in 6-month intervals
Daphna Y. Spiegel, Matthew J. Boyer, Julian C. Hong, Christina D. Williams, Michael J. Kelley, Joseph K. Salama, and Manisha Palta
resection and consideration of adjuvant chemotherapy (AC) based on patient and tumor characteristics. The role of AC in colon cancer is supported by the results of NSABP C01, 1 a pooled analysis, 2 and the MOSAIC trial 3 showing improvement in disease
Seanthel Delos Santos, Noah Witzke, Bishal Gyawali, Vanessa Sarah Arciero, Amanda Putri Rahmadian, Louis Everest, Matthew C. Cheung, and Kelvin K. Chan
assessed at the time of primary publication and at 3 years post-FDA approval using all publicly available data in eligible subsequent publications. Results Characteristics of Included Studies Of 113 indications that met the eligibility criteria, there were
Ritesh R. Kotecha, Ronan Flippot, Taylor Nortman, Annalisa Guida, Sujata Patil, Bernard Escudier, Robert J. Motzer, Laurence Albiges, and Martin H. Voss
clinical variables. R version 3.6.1 (R Foundation for Statistical Computing) was used for statistical analyses. Results Patient Characteristics From 2001 through 2019, 68 clinical trials conducted at Gustave Roussy and Memorial Sloan Kettering
